Persuading natural killer cells to eliminate bad B cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19638468.
- Also identified by DOI 10.1158/1078-0432.CCR-09-0966 and PMC identifier 2730884.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR) to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19(+) tumors.
Medical subject headings
- Antigens, CD19
- B-Lymphocytes
- Killer Cells, Natural
- Receptors, Antigen
- Recombinant Fusion Proteins
- T-Lymphocytes